<h4>Purpose</h4>Studies comparing the effect of aromatase inhibitor (AI) and tamoxifen use on cardiovascular disease (CVD) risk factors in hormone-receptor positive breast cancer (BC) survivors report conflicting results. This evidence concerns the gene CYP19A1 and cardiovascular disorder.